<SEC-DOCUMENT>0001731122-20-000488.txt : 20200513
<SEC-HEADER>0001731122-20-000488.hdr.sgml : 20200513
<ACCEPTANCE-DATETIME>20200513083533
ACCESSION NUMBER:		0001731122-20-000488
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200513
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20200513
DATE AS OF CHANGE:		20200513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enochian Biosciences Inc
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38758
		FILM NUMBER:		20871170

	BUSINESS ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DanDrit Biotech USA, Inc.
		DATE OF NAME CHANGE:	20140214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Putnam Hills Corp.
		DATE OF NAME CHANGE:	20110810
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e1916_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0 45pt 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 45pt 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
<B>May 13, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>ENOCHIAN BIOSCIENCES INC.</U></B><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>000-54478</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>45-2559340</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(State or other jurisdiction</FONT></TD>
    <TD STYLE="text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">of incorporation)</FONT></TD>
    <TD STYLE="text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 106%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2080 Century City East</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Suite 906</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Los Angeles, CA 90067</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>+1(786) 888-1685</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 106%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt; line-height: 106%">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt; line-height: 106%">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt; line-height: 106%">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt; line-height: 106%">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Title of Each Class </U></B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Trading Symbol </U></B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Name of Each Exchange on Which Registered </U></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENOB</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 45pt 8pt 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 45pt 8pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 13, 2020, Enochian Biosciences, Inc. issued a press release
announcing three scientific presentations on studies related to potential HIV and HBV cures to be given at the Annual Meeting of
the American Society of Cell and Gene Therapy. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The information included in this Item 8.01 and in Exhibit 99.1 shall
not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT NO.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LOCATION</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 13%"><A HREF="e1916_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%"><A HREF="e1916_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated May 13, 2020</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%"><A HREF="e1916_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENOCHIAN BIOSCIENCES, INC.</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 65%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark R. Dybul</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Mark R. Dybul<BR>
Title: Executive Vice Chair</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">Date:&nbsp;May 13, 2020</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 45pt 0 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 45pt 0 0.5in"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>e1916_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0">Exhibit 99.1</P>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 0 0 12.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 55px; width: 73px"></FONT></P>

<P STYLE="font: 4.5pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 4.95pt 0 0 5.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; font-style: normal; font-weight: normal">Enochian
Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt/7.35pt Times New Roman, Times, Serif; margin-top: 7.15pt; margin-bottom: 0"><TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 5.55pt"></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 4pt"><FONT STYLE="font-size: 6.5pt">&bull;</FONT></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif"><B><I>First presentation of a novel approach to potentially cure HIV</I></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 9pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 9.1pt"></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 5.7pt"><FONT STYLE="font-size: 6.5pt">-</FONT></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif"><B>An <I>in vivo </I>study demonstrated a 164 percent increase in engraftment of genetically
modified cells</B></TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0 0 20pt; font: 9pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#111;</FONT><B>&nbsp;Poster
Presentation - <FONT STYLE="color: #541A8B; letter-spacing: -3.95pt">h</FONT></B><FONT STYLE="color: #541A8B">h<B>ttp://www.enochianbio.com/wp-content/uploads/2020/05/Final-Poster-SyngeneicMouse_431_ASGCT_Poster_Final-05112020-2.pdf
</B></FONT></P>

<P STYLE="margin: 0pt 0 0 20pt; font: 9pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#111;</FONT><B>&#8239;&#8239;Slide
Presentation - <FONT STYLE="color: #541A8B; letter-spacing: -3.95pt">h</FONT></B><FONT STYLE="color: #541A8B">h<B>ttp://www.enochianbio.com/wp-content/uploads/2020/05/Final-Presentation-SyngeneicMouse_431_ASGCT_Final-05112020.pdf</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; width: 100%; margin-top: 6.25pt; margin-bottom: 0"><TR STYLE="font: 9pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 9.1pt"></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 5.7pt"><FONT STYLE="font-size: 6.5pt">-</FONT></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif"><B>A second study provides an in-depth explanation for how the increase in engraftment occurred</B></TD></TR>
</TABLE>

<P STYLE="margin: 0 0 0 20pt; font: 9pt Times New Roman, Times, Serif">&#111;&nbsp;Poster Presentation
<B>- <FONT STYLE="color: #541A8B; letter-spacing: -3.95pt">h</FONT></B><FONT STYLE="color: #541A8B">h<B>ttp://www.enochianbio.com/wp-content/uploads/2020/05/FINAL-InVitroChemoselection_ASGCT_Poster1219_05112020_RH.pdf
</B></FONT></P>

<P STYLE="margin: 0 0 0 20pt; font: 9pt Times New Roman, Times, Serif">&#111;<B>&nbsp;Slide&nbsp;Presentation
- <FONT STYLE="color: #541A8B; letter-spacing: -3.95pt">h</FONT></B><FONT STYLE="color: #541A8B">h<B>ttp://www.enochianbio.com/wp-content/uploads/2020/05/InVitroChemoSelection_1219_ASGCT_Presentation_05112020.pdf</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; width: 100%; margin-top: 6.25pt; margin-bottom: 0"><TR STYLE="font: 9pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 5.55pt"></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; width: 5.8pt"><FONT STYLE="font-size: 6.5pt">&bull;</FONT></TD><TD STYLE="font: 9pt Times New Roman, Times, Serif"><B><I>An innovative potential cure for Hepatitis B virus (HBV) infection</I></B></TD></TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 9.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>-
In vivo </I>studies validate previously reported <I>in vitro </I>results showing an average killing of up to 97 percent of HBV-infected
cells</B></FONT>&nbsp;</P>

<P STYLE="margin: 0 0 0 20pt; font: 9pt Times New Roman, Times, Serif">&#111;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Poster
                                         Presentation</B></FONT><B> - <FONT STYLE="color: #541A8B">http://www.enochianbio.com/wp-content/uploads/2020/05/HBV_592_ASGCT_Poster_-Final_05112020.pdf
                                         </FONT></B></P>

<P STYLE="margin: 0 0 0 20pt; font: 9pt Times New Roman, Times, Serif"><B></B>&#111;&nbsp;<B>Slide&nbsp;Presentation
- <FONT STYLE="color: #541A8B">http://www.enochianbio.com/wp-ontent/uploads/2020/05/HBV_592_ASGCT_Presentation_FinalCorrect.pdf</FONT></B></P>


<P STYLE="font: 6.5pt/96% Times New Roman, Times, Serif; margin: 0 141pt 0 22.65pt"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 5.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0 5.2pt 0 5.55pt; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">LOS
ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences (NASDAQ:ENOB), a company focused on gene-modified cellular therapy
in infectious disease and cancer, announces three scientific presentations given yesterday at the Annual Meeting of the American
Society of Gene and Cell Therapy (ASGCT). All three abstracts submitted to the conference were accepted for presentation.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 0 0 5.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
Potential Cure for HIV</I></B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 6.2pt 0 0 5.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than 39 million people live with HIV worldwide. There were approximately 2 million deaths and 1 million new infections last year.</FONT></P>

<P STYLE="text-align: justify; font: 6.5pt Times New Roman, Times, Serif; margin: 6.2pt 0 0 5.55pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Two presentations provide the first description of a novel approach to potentially cure HIV. Genetic modification of cells
to overexpress an important enzyme (ALDH1) protected them from dying when they were treated with low doses of a chemotherapeutic
drug, cyclophosphamide. This innovative strategy resulted in a one hundred and sixty-four percent (164%) increase in engraftment
of transplanted cells in a mouse model.&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 6.5pt Times New Roman, Times, Serif; margin: 6.2pt 0 0 5.55pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At the HEP DART meeting in December 2019, we showed that a novel approach killed up to 97 percent of cells infected with HBV
in vitro. Today, we presented new data from several in vivo studies providing a further scientific foundation for the mechanism
of action of that killing and further validation of the approach as a potential therapy to cure HBV.&nbsp;</FONT></P>

<P STYLE="font: 5.5pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 0 0 5.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
Potential Cure for HBV</I></B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 6.2pt 0 0 5.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
257 million or five percent (5%) of the people in the world are infected with HBV, and nearly 1 million people die per year.</FONT></P>

<P STYLE="font: normal 10pt/7.35pt Times New Roman, Times, Serif; margin: 6.25pt 0 0 5.55pt; text-align: justify"></P>

<P STYLE="font: normal 10pt/96% Times New Roman, Times, Serif; margin: 0 5.4pt 0 5.55pt; text-align: justify">At the HEP DART meeting in December 2019, we showed that a novel approach killed up to 97 percent of cells infected with HBV
in vitro. Today, we presented new data from several in vivo studies providing a further scientific foundation for the mechanism
of action of that killing and further validation of the approach as a potential therapy to cure HBV.</P>

<P STYLE="font: normal 10pt/96% Times New Roman, Times, Serif; margin: 0 5.4pt 0 5.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt/96% Times New Roman, Times, Serif; margin: 0 5.4pt 0 5.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;As
we do not have a cure for HIV or HBV, this new research is compelling. Currently, we have good oral, safe and effective therapies
that patients with HIV or chronic HBV must take daily, for life. This is challenging for many individuals. Non-compliance can
lead to HIV and HBV viral resistance or to acute liver flares in patients with chronic liver disease. Patients and physicians
all look to a future that could offer a cure.&rdquo; <B><I>Carol L. Brosgart, MD, Clinical Professor of Medicine, Epidemiology
and Biostatistics, University of California, San Francisco and a member of the Enochian Board of Directors.</I></B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 0 0 5.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Forward-Looking
Statements</I></B></FONT></P>

<P STYLE="font: 5.5pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: normal 10pt/96% Times New Roman, Times, Serif; margin: 0 5.2pt 0 5.55pt; text-align: justify">Statements in this press
release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based
on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success
or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified
by the use of forward-looking terminology such as &ldquo;believes,&rdquo; plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;aims,&rdquo;
&ldquo;intends&rdquo; &ldquo;potential,&rdquo; or similar expressions. Actual events or results may differ materially from those
projected in any of such statements due to various uncertainties, including as set forth in Enochian&rsquo;s most recent Annual
Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by <FONT STYLE="letter-spacing: -0.2pt">this
</FONT>cautionary statement, and Enochian undertakes no obligation to revise or update this press release to reflect events or
circumstances after the date hereof.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 4.1pt 0 0 5.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact:
ir@enochianbio.com</FONT></P>



<P STYLE="font-family: Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  W $D# 2(  A$! Q$!_\0
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:W$MQCS'>1G9@,X&23P,FBBBX&A1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
